Human interleukin 3 (IL-3) variants generated by site-directed mutgeness were analyzed in multiple biological and binding assays to identify residues critical for IL-3 activity. model where the C terminus of IL-3 interacts with the a chain of the IL-3 receptor, making this region a useful focus for the development of more potent IL-3 agonists or antagonists.
Interleukin 3 (IL-3) is a T-cell-derived glycoprotein of 133 amino acids that is central in the control of hemopoiesis and inflammation (1) . In vitro studies showed that IL-3 stimulates the proliferation and differentiation of normal hemopoietic cells of different lineages directly (2) (3) (4) (5) and in combination with lineage-restricted growth factors (6) , granulocytemacrophage colony-stimulating factor (GM-CSF), and mast cell growth factor (7) . In vivo, IL-3 alone elevates the numbers of several hemopoietic cell lineages in the blood (8) (9) (10) and can also act synergistically with GM-CSF (11) . Because of its pleiotropic effects, IL-3 appears ideally suited for clinical application in situations where extensive bone marrow reconstitution is required. On the other hand, IL-3 is likely to play a regulatory role in inflammatory conditions through its activation ofmature cell function. For example, IL-3 can affect the migration ofmonocytes to sites ofinflammation by modulating their adherence to endothelial cells (12) , and through its enhancement of histamine release on basophils, IL-3 can significantly exacerbate allergic reactions (13, 14) .
Despite its multiple biological activities, it is not clear how IL-3 exerts its effects on various cell types. Cell surface receptors for IL-3 have been identified on several primary cells (14) (15) (16) (17) (20) on a synthetic human IL-3 cDNA in an M13 vector (21) or polymerase chain reaction (PCR) mutagenesis (22) . A two-part PCR using three primers (22) was used to create mutants in the expression vector pJLA+IL-3 as described (21) . IL-3 analogs created by site-directed mutagenesis were subcloned into BamHI-EcoRI sites of pJL4 (21 (24) . Wild-type IL-3 and the analog [Alal0lVal"6]IL-3 were expressed in the E. coli system after induction by isopropyl f-D-thiogalactoside; protein was recovered from the periplasmic space by osmotic shock (25) and partially purified by gel filtration. IL-3 protein detection was carried out by Western blot analysis using a rabbit anti-human IL-3 (gift from S. Clark, Genetics Institute, Cambridge, MA) and visualized by autoradiography after the addition of 125I-labeled protein A (26) .
Quantitation of IL-3 Protein. The amount of IL-3 protein present in COS cell supernatants was quantitated by a competitive radioimmunoassay (RIA) using human IL-3 (a gift from L. Park, Immunex, Seattle) labeled with 125I and an anti-IL-3 serum (gift from S. Clark, Genetics Institute) as Abbreviations: IL-3, interleukin 3; CML, chronic myeloid leukemia; GM-CSF, granulocyte-macrophage colony-stimulating factor.
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described (27) . Wild-type IL-3 and [Ala101,Val116]IL-3 produced in E. coli were also quantitated directly by scanning densitometry (28) . Briefly, wild-type IL-3, [Ala101,Val116]IL-3, or RNase standards were electrophoresed over a concentration range of 0.5-5 ,ug, and the gel then was stained with Coomassie brilliant blue R250 and analyzed using an LKBPharmacia Ultrascan XL scanning laser densitometer. Data analysis was performed with GSXL densitometer software. The protein concentrations of the unknown samples were calculated using the area under the peak. In some cases direct protein quantitation was also performed by HPLC peak integration by calculating the area under the IL-3 peak using the extinction coefficient of 0.83 arbitrary units ml mg-1. An IL-3 preparation (gift from Genetics Institute) at 0.6 pug/ml (ii) Proliferation ofchronic myeloid leukemic (CML) cells. CML cells incorporated [3H]thymidine in response to IL-3 as described (29) . Data are expressed in cpm, and each point is the mean of six replicates.
Stimulation of Human Monocyte and Basophil Function. Monocytes were purified from the peripheral blood of normal donors as described (16) and IL-3-mediated adhesion was measured by an isotopic method as described (12) . Basophil histamine release was measured as described (14) .
Radioreceptor Assay. Human IL-3 (gift from L. Park, Immunex) was radioiodinated by the ICI method (30) and used in competitive binding experiments as described (16, 31) . The results are expressed as percent competition, where 100% is the competition observed in the presence of a 100-fold excess of wild-type IL-3.
Statistical Analysis. Each mutant was tested over a range of concentrations using three to six replicates per point, and the concentration of IL-3 analog giving 50% maximal response was determined. Percent potency was calculated by dividing the concentration of wild-type IL-3 giving 50% maximal response by the concentration of IL-3 mutant giving 50% maximal response x 100%6. Significance was established by one-way analysis of variance using the 50% values of at least three experiments for each assay. RESULTS Predictive studies of human IL-3 structure (32, 33) indicated that this molecule contains four a-helices and several hydrophilic regions (Fig. 1 ). Since these regions have been implicated in function and receptor binding of related growth factors such as GM-CSF (24, (34) (35) (36) and growth hormone (37), they were targeted for mutagenesis. IL-3 cDNA mutants were expressed transiently in COS cells, and Western blot analysis revealed that IL-3 mutants and wild-type IL-3 exhibited similar size and levels of glycosylation (data not shown).
Biological Analysis of N-Terminal Mutations. Mutation of residues Asp21, Glu22, and Thr25 located in a hydrophilic region of the predicted first a-helix of IL-3 to Ala, Leu, and Ala, respectively, was predicted to reverse the hydropathy of this region (Fig. 1) . The two IL-3 mutants tested, [Ala21,Leu22]IL-3 and [Ala21,Leu22,Ala25JIL-3 were unable to stimulate the proliferation of CML cells, monocyte adherence, and histamine release from basophils (Table 1) or to bind to the high-affinity IL-3 receptor ofmonocytes ( Table 2) .
Mutations in a different hydrophilic region comprising residues Asp44, Gln45, and Asp46 also led to a predicted inversion ofhydropathy. In this case, the IL-3 mutants [Ala44,Ala6]-and [Ala",Leu45,Ala4eIIL-3 exhibited properties similar to wildtype IL-3 in stimulating CML cell proliferation, monocyte adherence, and basophil histamine release (Table 1) .
Biological Analysis of C-Terminal Mutations. Initial deletion mutagenesis revealed that the 13 most C-terminal residues of IL-3 were not essential for activity (Table 1) [Val116]IL-3 that were more active than wild-type IL-3 also exhibited increased binding affinity (Table 2 ). These two mutations were then incorporated into a single molecule and tested in biological and binding assays.
Bilgical and Binding Properties of [Ala"01,Val"1'6IL-3. The mutant [Ala101,Val"6]IL-3 was 10-to 20-fold more potent than wild-type IL-3 at stimulating CML cell proliferation ( Fig. 2A and Table 1 ) and bone marrow colonies (Fig. 2B) . Greater potency by [Ala'01,Val'16]IL-3 was also observed in the stimulation of monocyte adherence (Fig. 3A and Table 1) and basophil histamine release (Fig. 3B and Table 1 ). This increased potency was reflected in the increased ability of [Ala'01,Va1116]IL-3 to recognize the high-affinity IL-3 receptor of monocytes (Table 2) .
Because high-affinity IL-3 receptors contain a low-affinity receptor binding chain and a convertor ,B chain (38) , it was important to establish whether [Ala101,Val116]IL-3 was exhibiting increased affinity as a result of increased binding to the low-affinity IL-3 component. To determine this, we used 1251-labeled IL-3 at 2 nM, a concentration at which the majority of occupied receptors in human monocytes are of the low-affinity class (16, 31) . For these experiments, [Ala101,Val116]IL-3 and wild-type IL-3 were expressed in E. coli, partially purified by gel filtration, and tested in conjunction with purified E. coli-derived IL-3 (gift from S. Clark, Genetics Institute) for their ability to inhibit the binding of 2 nM 125I-labeled IL-3 to human monocytes. A quantitative inhibition binding experiment showed that [Ala'01,Val'16]IL-3 has a 15-fold greater affinity than wild-type IL-3 in binding to human monocytes under low-affinity conditions (Fig. 4) These results show that the potential to generate IL-3 analogs with increased potency appears to be restricted so far to substitution of residues at positions 101 and 116, inasmuch as mutations at positions 104, 105, and 108 (Tables 1 and 2) and replacement of residues Lys110 or Leu1l (19) and Glu106 (39) greatly reduce the potency of IL-3. These results are consistent with other structure-function studies on IL-3 (40) and on GM-CSF and IL-5 where the C terminus has been shown to be required for functional integrity (34) (35) (36) 41) [44] [45] [46] are not (Fig. 1) or that residues 21 and 22 are directly involved in binding and function. In support of the latter, it is worth noting that both IL-3 and GM-CSF interact with their respective specific a chains (38, 42) and with a chain that is common to both ligands (38, 43) . Glu22 is in a predicted exposed face of the first a-helix of IL-3 and is in an analogous position to Glu21 in GM-CSF (33) . Since the mutation of Glu21 in GM-CSF impaired binding to the chain while fully retaining binding to the a chain (24) , it is likely that similar substitutions at position 22 in IL-3 will also selectively affect binding to the chain.
The mechanism by which [Ala101,Val'16]IL-3 stimulates function with greater potency is not known but is probably related to its increased binding to high-affinity IL-3 receptors (Table 2) . Since these are composed of at least two chains, a low-affinity a chain and a convertor chain (38) (45) and in follicular cell tumors where IL-3 binds and promotes their growth (46) .
